

## BC Cancer ST Program Updates for January, 2022

<b>AFFECTED APPLICATION(S)</b>	<b>PowerChart: Oncology/Hematology Regimens and PowerPlans</b>
<b>AFFECTED AREA(S)</b>	<b>BC Cancer VC (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)</b>
<b>NET NEW, OR UPDATE TO EXISTING BUILD</b>	<b>Update to Existing Build</b>


### What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

### For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
  - Click **Yes** to accept the new version
  - **Do not** use the Copy Forward functionality to ensure that the updates apply



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning)

Please see this month's changes below.

**PowerPlan:** UGIFIRPAN, UGIFFOXPAN, UGISORAF, UGIGAVTRFT, UGILEN, UGINFOCLAR, UGIOCTLAR, USMAVIPNI, USMAJPEM, USMAJPEM6, USMAJNIV, USMAJNIV4, USMAJDT, USMAVVIS, USMAVCEM, UGUAVPEM, UGUAVPEM6, ULUAVCER, ULUAVOSI, ULUAVPPMB, ULUAVOSIF, ULUAVPCPMB, ULUAVPGPMB, UBRAVKAD

**Cycles/PowerPlans:** All Associated PowerPlans and Regimens

**Changes:**

CAP designation of these protocols will be removed on January 4, 2022

New Names in Cerner

UGIFIRPAN → GIFFIRPAN  
UGIFFOXPAN → GIFFOXPAN  
UGISORAF → GISORAF  
UGIGAVTRFT → GIGAVTRFT  
UGILEN → GILEN  
UGINFOCLAR → GINFOCLAR  
UGIOCTLAR → GIOCTLAR  
USMAVIPNI → SMAVIPNI  
USMAJPEM → SMAJPEM  
USMAJPEM6 → SMAJPEM6  
USMAJNIV → SMAJNIV  
USMAJNIV4 → SMAJNIV4  
USMAJDT → SMAJDT  
USMAVVIS → SMAVVIS  
USMAVCEM → SMAVCEM  
UGUAVPEM → GUAVPEM  
UGUAVPEM6 → GUAVPEM6  
ULUAVCER → LUAVCER  
ULUAVOSI → LUAVOSI  
ULUAVPPMB → LUAVPPMB  
ULUAVOSIF → LUAVOSIF  
ULUAVPCPMB → LUAVPCPMB  
ULUAVPGPMB → LUAVPGPMB  
UBRAVKAD → BRAVKAD

**Versioning:** Yes

**Jira:** CST-149749

## PowerPlan: HNLACART

**Cycles/PowerPlans:** All Associated PowerPlans and Regimens

### Changes:

Protocol name for HNLACART has been changed to HNLACARTW

Regimen description updated to: Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent **Weekly** CARBOplatin and Radiation

ONC HN HNLACARTW (Pending)

▼ Hide additional details

Regimen description: Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly CARBOplatin and Radiation

+ Add Document Response View Responses

ONCP HN HNLACARTW Pretreatment Plan

Start

- ONCP HN HNLACARTW - Cycle 1
- ONCP HN HNLACARTW - Cycle 2
- ONCP HN HNLACARTW - Cycle 3
- ONCP HN HNLACARTW - Cycle 4
- ONCP HN HNLACARTW - Cycle 5
- ONCP HN HNLACARTW - Cycle 6
- ONCP HN HNLACARTW - Cycle 7

Powerplan link to protocol description updated to: Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent **Weekly** CARBOplatin and Radiation

ONCP HN HNLACARTW - Cycle 1, Chemotherapy (Day 1) (Future Pending) \*Es

Component
Link to Protocol: Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly CARBOplatin and Radiation

**Versioning:** Yes

**Jira:** CST-148496

## PowerPlan: LUMMPP, LUAVPPMB

**Cycles/PowerPlans:** LUMPP Treatment Powerplans, LUAVPPMB Treatment Powerplans

### Changes:

In the pre-medication section, removed "Patient to take dexamethasone 4 mg PO BID for 3 days starting one day prior to treatment" from the first blue note.

Above ondansetron, added dexamethasone order with 8mg and 12mg order sentences

ONCP LU LUMMPP CARBOplatin Option Cycles 1 to 2 - Cycle 1, Chemotherapy (Day 1) (Future Pending) \*Est. 01-J-

Component
Link to Protocol: Treatment of Malignant Mesothelioma with Platinum and Pemetrexed
Revised: 4 Jan 2022
Pre-Chemo Metrics
Neutrophils Greater Than or Equal to $1.5 \times 10^9/L$ within 96 hours
Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 96 hours
Pre-Medications
Patient to take own supply of pre-medications. RN/Pharmacist to confirm
Ensure patient is taking folic acid and has had vitamin B12 injection starting at least 7 days prior to first cycle, and to continue while on treatment, until 21 days after last pemetrexed dose. Patient to obtain supply
<input checked="" type="checkbox"/> dexamethasone
<input checked="" type="checkbox"/> 8 mg, PO, once oncology, drug form: tab, first dose: Routine, Use Patient Supply
8 mg, PO, once oncology, drug form: tab, Use Patient Supply
12 mg, PO, once oncology, drug form: tab, Use Patient Supply
6 mg, PO, once oncology, drug form: tab, Use Patient Supply
Between 30 and 60 minutes prior to treatment. Day 1
If low respiratory saturation has occurred, use treatment as per Cancer Respiratory Support...

**Versioning:** Yes

**Jira:** CST-148229

## PowerPlan: LUAVPP

### Cycles/PowerPlans: Treatment PowerPlans

#### Changes:

In the pre-medication section, removed "Patient to take dexamethasone 4 mg PO BID for 3 days starting one day prior to treatment" from the first blue note

Above ondansetron, added dexamethasone order with 8mg and 12mg order sentences

ONCP LU LUAVPP CARBOplatin Option Cycles 1 and 2 - Cycle 1, Chemotherapy (Day 1) (Future Pending) \*Est. 01-

Component
Link to Protocol: First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed
Revised: 4 Jan 2022
Pre-Chemo Metrics
Neutrophils Greater Than or Equal to $1.5 \times 10^9/L$ within 96 hours
Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 96 hours
Pre-Medications
Patient to take own supply of pre-medications. RN/Pharmacist to confirm
Ensure patient is taking folic acid and has had vitamin B12 injection starting at least 7 days prior to first cycle, and to continue while on treatment, until 21 days after last pemetrexed dose. Patient to obtain supply
<input checked="" type="checkbox"/> dexamethasone
<input type="checkbox"/> 8 mg, PO, once oncology, drug form: tab, Use Patient Supply
<input checked="" type="checkbox"/> 8 mg, PO, once oncology, drug form: tab, Use Patient Supply
<input checked="" type="checkbox"/> 12 mg, PO, once oncology, drug form: tab, Use Patient Supply
<input type="checkbox"/> 4 mg, PO, once oncology, drug form: tab, Use Patient Supply
Between 30 and 60 minutes prior to treatment. Day 1

Split Powerplans into Cycles 1 and 2 and Cycles 3+ for both CARBOplatin and CISplatin options

- ONCP LU LUAVPP CARBOplatin Option Cycles 1 and 2
- ONCP LU LUAVPP CARBOplatin Option Cycles 3+
- ONCP LU LUAVPP CISplatin Option Cycles 1 and 2
- ONCP LU LUAVPP CISplatin Option Cycles 3+

Versioning: Yes

Jira: CST-148227

**PowerPlan: KSLDO**

**Cycles/PowerPlans: KSLDO Treatment Plan**

**Changes:**

Added optional dexamethasone, diphenhydramine, and famotidine under a yellow note "If prior DOXOrubicin pegylated liposomal drug reaction:"

ONCP KS KSLDO - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 01-Jan-2022 08:00 PST - 14 Days			Day 1
		Component	Future Pending *Est. 01-Jan-2022 08:00 PST - 14 Days
<b>Pre-Medications</b>			
<input type="checkbox"/>		prochlorperazine 10 mg, PO, once oncology, drug form: tab 30 to 60 minutes prior to treatment. Day 1	-30 min
<input type="checkbox"/>		metoclopramide 10 mg, PO, once oncology, drug form: tab 30 to 60 minutes prior to treatment. Day 1	-30 min
<input type="checkbox"/>		<b>If prior DOXOrubicin pegylated liposomal drug reaction:</b> dexamethasone 20 mg, IV, once oncology, administer over: 15 minute, drug form: inj 45 minutes prior to DOXOrubicin pegylated liposomal. Day 1	-45 min
<input type="checkbox"/>		diphenhydrAMINE 50 mg, IV, once oncology, administer over: 15 minute, drug form: inj Y-site compatible with famotidine. 30 minutes prior to DOXOrubicin pegylated liposomal. Day 1	-30 min
<input type="checkbox"/>		famotidine 20 mg, IV, once oncology, administer over: 15 minute, drug form: inj Y-site compatible with diphenhydrAMINE. 30 minutes prior to DOXOrubicin pegylated liposomal. ...	-30 min

Updated all pre-chemo metrics to be within 72 hours from 24 hours

ONCP KS KSLDO - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 01-Jan-2022 08:00 PST - 14 Days		
		Component
		Link to Protocol: Therapy of Kaposi Sarcoma using DOXOrubicin Pegylated Liposomal
		Revised: 4 Jan 2022
<b>Pre-Chemo Metrics</b>		
		Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$ within 72 hours
		Platelet Count Greater Than or Equal to $75 \times 10^9/L$ within 72 hours
<b>Pre-Medications</b>		

**Versioning: Yes**

**Jira: CST-148149**

## PowerPlan: UGIPRRT

**Cycles/PowerPlans:** All Associated PowerPlans and Regimens

### Changes:

Updated Regimen description to:

Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium <sup>177</sup>Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours

ONC GI UGIPRRT (Pending)

▼ Hide additional details

Regimen description: Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177 Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours

A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment

Updated Powerplan link to protocol note to:

Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium <sup>177</sup>Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours

ONCP GI UGIPRRT - Cycle 1, Nuclear Medicine (Day 1) (Future Pending) \*Est. 01-Jan-2022 08:00 PST - 56 Day

	Component
	<a href="#">Link to Protocol: Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177 Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours</a>

Updated blue note under octreotide by adding "Lutetium" before 177-Lu-Dotatate

octreotide

▼ Select an order sentence

Patient must be kept in radiation isolation for a period of 4-5 hours following administration of Lutetium 177-Lu-Dotatate (LUTATHERA) and discharge dose rate must be less than 25 microSv/hr at 1 meter distance

Please contact PET department at 675902/ 675953/ 675951 and Radiation Safety Officer if spill occurs

**Versioning:** No

**Jira:** CST-148132

## PowerPlan: LYVIPDRT

### Cycles/PowerPlans: All Associated PowerPlans and Regimen

#### Changes:

In the Regimen:

- Changed Cycle 2 offset to 7 weeks from start of cycle 1

ONCP LY LYVIPDRT Pretreatment Plan	*Est. Start Date: 31-Dec-2021
<input type="button" value="Start"/>	<input type="button" value="Skip"/>
ONCP LY LYVIPDRT Cycle 1 - Cycle 1	*Est. Start Date: 31-Dec-2021
ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 2	*Est. Start Date: 18-Feb-2022
ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 3	*Est. Start Date: 11-Mar-2022
ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 4	*Est. Start Date: 01-Apr-2022
<input type="button" value="Extend"/>	

In the Cycle 1 plan:

- Added a 4 week option to the Follow Up - Clinic - Oncology On Treatment order

ONCP LY LYVIPDRT Cycle 1 - Cycle 1, Scheduling (Initiated Pending)	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY, Chair Time: 175 minutes, Nurse Time: 55 minutes, ONCP LY LYVIPDRT Cy Day 1
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY, Chair Time: 160 minutes, Nurse Time: 40 minutes, ONCP LY LYVIPDRT Cy Day 8
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY, Chair Time: 160 minutes, Nurse Time: 40 minutes, ONCP LY LYVIPDRT Cy Day 15
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY, Chair Time: 160 minutes, Nurse Time: 40 minutes, ONCP LY LYVIPDRT Cy Day 22
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Go to Chemo Calendar to send next cycle to scheduling wait list Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma Follow Up: 4 weeks, Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma

- Removed all labs except CBC and Differential and Creatinine Level and prechecked those for Days 8, 15, 22, 49

ONCP LY LYVIPDRT Cycle 1 - Cycle 1, Labs (Day 8, 15, 22, 49) (Future Pending) *Est. 27-Jan-2022 08:00 PST - 49 Days					
		Day 8	Day 15	Day 22	Day 49
	Component	Future Pending *Est. 27-Jan-2022 08:00...	Future Pending *Est. 03-Feb-2022 08:00...	Future Pending *Est. 10-Feb-2022 08:00...	Future Pending *Est. 09-Mar-2022 08:00...
		Actions	Actions	Actions	Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit	Planned	Planned	Planned	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit	Planned	Planned	Planned	Planned

In the Cycles 2 to 4 plan:

- Added a blue note "Patient to take therapeutic dexamethasone (see prescriptions phase) prior to treatment on day 1 and in AM on subsequent days" under the ondansetron order
- Removed dexamethasone order from the pre-medications
- Removed yellow note "No extra dexamethasone since patient is already on dexamethasone 40 mg daily on Days 1 to 4"



ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 2, Chemotherapy (Day 1 to 3) (	
Component	
<b>Pre-Medications</b>	
Patient to take own supply of pre-medications. RN/Pharmacist to confirm	
<input checked="" type="checkbox"/>	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to treatment. Days 1, 2, 3
Patient to take therapeutic dexamethasone (see prescriptions phase) prior to treatment on day 1 and in AM on subsequent days	
<input type="checkbox"/>	hydrocortisone 100 mg, IV, once oncology, drug form: inj Prior to etoposide. Days 1, 2, 3
<input type="checkbox"/>	diphenhydrAMINE 50 mg, IV, once oncology, drug form: inj Prior to etoposide. Days 1, 2, 3

- Added a 3 week option to the Follow Up - Clinic - Oncology On Treatment order

ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 2, Scheduling (Initiated Pending)	
<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Cycle 2: Chair time 300 minutes; Nurse time 80 minutes, Chair Time: 27: Day 1
<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY, Chair Time: 275 minutes, Nurse Time: 55 minutes, ONCP LY LYVIPDRT ( Day 2
<input checked="" type="checkbox"/>	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY, Chair Time: 275 minutes, Nurse Time: 55 minutes, ONCP LY LYVIPDRT ( Day 3
<input checked="" type="checkbox"/>	Follow Up - Clinic - Oncology On Treatment Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma
<input checked="" type="checkbox"/>	Go to Chemo Calendar to send next cycle to scheduling wait list Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma Follow Up: 3 weeks, Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma

- Removed all labs except CBC and Differential and Creatinine Level

ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 2, Next Cycle Labs (Day 1)	
Component	
<input checked="" type="checkbox"/>	CBC and Differential Blood, once, Order for future visit
<input checked="" type="checkbox"/>	Creatinine Level Blood, once, Order for future visit

**Versioning:** Yes

**Jira:** CST-148066

<b>Jira Ticket #</b>	CST-149749, CST-148496, CST-148229, CST-148227, CST-148149, CST-148132, CST-148066
<b>How-to questions?</b>	<a href="http://cstcernerhelp.healthcarebc.ca">http://cstcernerhelp.healthcarebc.ca</a>
<b>Need further support?</b>	<b>CST Phone Support: 1-844-214-7444</b>